Price disclosure strikes again


De-listing of paracetamol from PBS is pure speculation

The latest round of PBS price disclosure cuts has been publicly released

A range of common medications are included in the April 2017 round of reductions, released yesterday, with some experiencing reductions of 25-30 per cent.

Heading the list are major cuts to the price of Rosuvastatin, Australia’s second most commonly dispensed medicine. It will experience drops of more than 35% across a range of different tablet sizes.

The angiotensin II receptor antagonists Candesartan and Telmisartan will also experience large price drops in the April round of cuts.

Among the medicines affected are:

  • Candesartan – with reductions of 28-29%, up to 36% for some formulations of Candesartan with hydrochlorothiazide.
  • Desvenlafaxine – oral tablets, with a reduction of over 28%
  • Diclofenac – reductions of 11.98% for tablet (enteric coated) containing diclofenac sodium 50 mg, and 12.18% for tablets containing diclofenac sodium 25mg.
  • Fentanyl transdermal patches – a range of products all with reductions of around 11.9%
  • Lamotrigine (tablets of 25 to 200mg) – reduced by 18.8%
  • Mometasone – cream, lotion and ointment – down by 20%
  • Olanzapine – in a wide range of tablet and wafer formulations, to drop by between 12.7 and 12.85%
  • Omeprazole – 20mg capsules and 10 and 20mg tablets, to reduce by around 13%
  • Pramipexole – down by 29%
  • Rosuvastatin – 5,10,20 and 40 mg tablets, to drop by more than 35%
  • Telmisartan with hydrochlorothiazide –   Tablet 40 mg-12.5 mg and 80 mg-25 mg will drop by more than 42%, and tablet 80 mg-12.5 mg by 38.84%
  • Zoledronic acid – down by 24.97%

The latest round is the ‘Second Remove Originator’ cycle which removes “originator brand” data from the price disclosure calculation depending on which results in the lowest new price.

An “originator brand” will usually be the first brand of a pharmaceutical item listed on F1 of the Pharmaceutical Benefits Scheme.

Removal of the “originator brand” from the calculation does not mean that that brand becomes exempt from price disclosure, the PBS advises.

The “originator brand” of a medicine will receive the same price reduction as calculated for the generic brands.

The April round of reductions does not include flow-on price disclosure reductions for combination drugs or F2 combination drugs.

Combination Drugs taking Flow-on Price Reductions for 1 April 2017 will be published on the Pricing Matters web page.

Click here for advice on techniques to offset the impact of PBS cuts.

Previous ADHD stigma a barrier to treatment
Next Medicines group calls for downscheduling

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.